9966 — Alphamab Oncology Income Statement
0.000.00%
Last trade - 00:00- HK$6.67bn
- HK$5.19bn
- CNY640.08m
- 43
- 22
- 97
- 56
Annual income statement for Alphamab Oncology, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 146 | 167 | 219 | 640 |
| Cost of Revenue | |||||
| Gross Profit | — | 143 | 123 | 164 | 580 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 416 | 545 | 478 | 417 | 464 |
| Operating Profit | -416 | -399 | -312 | -198 | 176 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -428 | -412 | -326 | -211 | 166 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -428 | -412 | -326 | -211 | 166 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -428 | -412 | -326 | -211 | 166 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -428 | -412 | -326 | -211 | 166 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.92 | -0.882 | -0.696 | -0.439 | 0.338 |